Filing Details Pacer Advisors, Inc., a registered investment adviser, increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 24.9% during Q1 2026, according to its most recent…
Pacer Advisors, Inc., a registered investment adviser, increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 24.9% during Q1 2026, according to its most recent 13F filing with the Securities and Exchange Commission.
The firm purchased an additional 308,633 shares of the Healthcare company, bringing its total holdings to 1,549,611 shares valued at approximately $66.5M as of the filing date.
Exelixis, Inc.'s stock currently trades at $54.74 with a market capitalization of $11.1B.
An increase in an existing position suggests Pacer Advisors, Inc. has growing conviction in Exelixis, Inc.'s trajectory. Institutional investors typically add to positions when they believe the stock still has upside relative to their price target, or when the company's fundamentals have improved since their initial purchase.
Healthcare stocks have attracted institutional attention as an aging population drives long-term demand. Exelixis, Inc. operates in a sector where regulatory developments and pipeline progress can significantly impact institutional positioning.
Investors should note that 13F filings reflect holdings as of the end of the reporting quarter and are filed up to 45 days later. The position may have changed since the filing date. 13F data is most useful when analyzed alongside other signals such as insider transactions, analyst ratings, and fundamental trends.
Related Tools: Insider Trades Tracker | View EXEL Stock Page
A 13F filing is a quarterly SEC report required for institutional managers with over $100 million in assets. It discloses equity holdings, providing transparency into how firms like Pacer Advisors, Inc. position their portfolios.
View all institutional holders on our EXEL institutional ownership page.
Current market data
NASDAQ · EXEL
$56.90
Up: +$0.59 · +1.04%
Live quote updated
Keep reading
